相关实验视频
Updated: May 23, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
738
格利利德在治疗基本血小板血方面:一个系统性审查和元分析
Barbara Abreu Lopez1, Joanne Arvelaez Pascucci2, Safiya Mohamed Ramzy3
1Universidad De Carabobo, Naguanagua, Venezuela.
International journal of hematology
|March 9, 2025
概括
与氧尿素相比,阿纳格利利德有效地降低了基本血小板计数 (ET) 的血小板计数,但携带更高的出血风险. 需要进一步的研究来确认ET患者的长期安全性和最佳剂量.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 基本血小板血 (ET) 是一种骨髓增殖性瘤.
- 氧尿素是一种常见的第一线治疗方法,而安格雷利德作为第二线选择.
- 与基尿素相比,阿纳格利利德的疗效和安全性需要进一步研究.
研究的目的:
- 进行系统性审查和元分析,比较ET治疗中的阿纳格利利德和基尿素.
- 为了评估与这两种药物相关的血小板减少,血栓栓塞事件和不良事件.
主要方法:
- 在多个数据库 (PubMed,Cochrane等) 中进行系统搜索. 在2024年10月之前.
- 包括随机对照试验和队列研究,比较阿纳格利利德和氧尿素.
- 遵守PRISMA系统审查指南.
主要成果:
- 亚纳格利利德显著降低了血小板数量,远远超过氧尿素 (MD-65.22,p<0.01).
- 两种药物之间的血栓事件没有显著差异 (RR1.34,p<0.01).
- 阳性JAK患者患血栓事件的发病率较高;不良事件发生率不同.
结论:
- 阿纳格利利德有效降低ET的血小板,但可能会增加出血风险,特别是在高风险患者中.
- 由于与阿纳格雷利德相关的潜在出血风险,建议谨慎使用.
- 需要进一步的研究来确定长期的安全性,并完善阿纳格雷利德的剂量策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
448
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
448
Anticoagulant Drugs: Low-Molecular-Weight Heparins
588
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
588
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
433
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
433
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antianginal Drugs: Nitrates and β-Blockers
486
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
486

